Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    neuroqore
Previous Study | Return to List | Next Study

NeuroQore rTMS (Monophasic vs. Biphasic) for Major Depressive Disorder: A Randomized Controlled Pilot Trial

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Dr. Verner Knott, University of Ottawa
Sponsor:
Collaborator:
NeuroQore Inc.
Information provided by (Responsible Party):
Dr. Verner Knott, University of Ottawa
ClinicalTrials.gov Identifier:
NCT02667041
First received: January 25, 2016
Last updated: November 3, 2016
Last verified: November 2016
  Purpose
Major depressive disorder (MDD) is a debilitating illness that affects millions of individuals in North America and can result in clinical symptoms including loss of pleasure and feelings of worthlessness, in addition to significant cognitive impairments (e.g., memory, attention) that affect daily functioning. Major depression bears a heavy burden for the individuals and family members afflicted, as well as an enormous health care and economic cost. Approximately half of major depressive patients seek out treatment for their illness and only 20% of those individuals report their treatment as satisfactory. Many MDD patients do not respond to pharmacological therapy following the first course of treatment, resulting in the need for alternative measures to alleviate the clinical and cognitive symptoms of treatment-resistant depression and the targeting of these therapies to better suit each individual patient. Repetitive transcranial magnetic stimulation (rTMS) is a well-accepted, non-invasive technique that utilizes currents to induce electrical fields that excite specific brain regions. The current recommended practice of rTMS involves the administration of a biphasic stimulus waveform; however, a novel method using monophasic pulses may prove more effective for the treatment of depression. The present study aims to determine the effect of monophasic rTMS compared to biphasic rTMS on cognitive processing in MDD patients through electrophysiological recordings of the brain taken before and after 6 weeks of stimulation. Additionally, the study aims to investigate various biological markers linked to clinical rTMS response; these brain markers will help in personalizing treatment for individuals suffering from MDD.

Condition Intervention
Depressive Disorder, Major
Device: NeuroQore rTMS Device

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: NeuroQore Repetitive Transcranial Magnetic Monophasic vs. Biphasic Stimulation For Major Depressive Disorder: A Randomized Controlled Trial

Further study details as provided by Dr. Verner Knott, University of Ottawa:

Primary Outcome Measures:
  • Montgomery-Åsberg Depression Rating Scale (MADRS) scores [ Time Frame: Six weeks ]

Estimated Enrollment: 40
Study Start Date: May 2015
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rTMS treatment (Monophasic vs. biphasic)
Safety and efficacy
Device: NeuroQore rTMS Device
Active Comparator: EEG/ERP biomarkers
Investigation of pre- and post-treatment cognitive biomarkers
Device: NeuroQore rTMS Device
Active Comparator: Blood biomarkers
Investigation of pre- and post-treatment protein biomarkers
Device: NeuroQore rTMS Device

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients will be included if they:

  1. are outpatients of the ROHCG
  2. are voluntary and competent to consent to treatment
  3. have a confirmed DSM-IV diagnosis of unipolar major depressive disorder
  4. are male or female
  5. are between the ages of 18 and 75
  6. have failed to achieve a clinical response to an adequate dose of an antidepressant in the current episode OR have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration
  7. have a score > 22 on the MADRS
  8. have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening
  9. are able to adhere to the treatment schedule
  10. pass the TMS safety screening questionnaire (TASS)
  11. have normal thyroid functioning based on pre-study blood work

Exclusion Criteria:

Patients will be excluded if they:

  1. have a history of substance dependence or abuse within the last 3 months or current substance use as indicated by a positive urine drug screen
  2. have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump
  3. have active suicidal intent
  4. are pregnant
  5. have a lifetime DSM-IV diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms
  6. have a DSM-IV diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, or personality disorder, assessed by a study investigator to be primary and causing greater impairment than MDD
  7. have failed a course of ECT in the current episode or previous episode
  8. have received rTMS for any previous indication due to the potential compromise of subject blinding
  9. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 5 minutes
  10. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
  11. if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study
  12. clinically significant laboratory abnormality, in the opinion of the investigator
  13. currently (or in the last 4 weeks) take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy
  14. non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview)
  15. failure of 3 or more adequate trials of medications of different drug classifications in the current episode
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02667041

Contacts
Contact: Molly Hyde, BSc 6137226521 ext 6254 molly.hyde@theroyal.ca

Locations
Canada, Ontario
Royal Ottawa Mental Health Centre Recruiting
Ottawa, Ontario, Canada, K1Z7K4
Contact: Molly Hyde, BSc    6137226521 ext 6254    molly.hyde@theroyal.ca   
Sponsors and Collaborators
University of Ottawa
NeuroQore Inc.
  More Information

Responsible Party: Dr. Verner Knott, Neuroelectrophysiology and Cognitive Research Laboratory, Director, University of Ottawa
ClinicalTrials.gov Identifier: NCT02667041     History of Changes
Other Study ID Numbers: 2015014
Study First Received: January 25, 2016
Last Updated: November 3, 2016

Additional relevant MeSH terms:
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms

ClinicalTrials.gov processed this record on May 25, 2017